Insulet (United States)
PODD
$139.30
+4.53%
Insulet Corporation is a medical device company that develops and markets the Omnipod system, a tubeless insulin pump for diabetes management, operating in the healthcare sector. As a pioneer in wearable insulin delivery technology, Insulet has established itself as a market leader with over 600,000 users worldwide, differentiating through its innovative, smartphone-controlled pod design. The company is currently navigating a critical period marked by a high-risk FDA recall of its flagship Omnipod 5 pods due to insulin delivery concerns, which has triggered significant investor scrutiny and a sharp decline in its stock price. Despite strong revenue growth and expanding profitability, the recall has cast a shadow over the company's near-term outlook, with management working to address manufacturing defects and restore confidence in its product safety and brand reputation.…
PODD
Insulet (United States)
$139.30
Related headlines
Investment Opinion: Should I buy PODD Today?
Rating: Hold. The stock is a high-risk, high-reward opportunity, with a consensus Buy rating and an average target of $235.54, but the recall introduces significant uncertainty. The thesis is that the company's strong growth and improving profitability are overshadowed by the recall, making it prudent to wait for clarity before committing capital. Supporting evidence includes Q1 2026 revenue growth of 33.9% YoY, net margin expansion to 12.0%, a forward PE of 20.5x (below the industry average of 22.5x), and a free cash flow of $86M in Q1. The stock is trading at a 42.5% discount to the average analyst target, but the wide range of targets ($172-$360) highlights the uncertainty. The biggest risks are the recall's impact on revenue growth, potential regulatory actions, and competitive pressures. This Hold would upgrade to Buy if the stock falls below $150 (a 10% discount to the low target) or if the recall is resolved with minimal financial damage, and downgrade to Sell if revenue growth decelerates below 10% or the recall expands. Overall, the stock is fairly valued on forward earnings but overvalued on trailing earnings, making it a speculative hold.
Sign up to view all
PODD 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock's strong growth and reasonable forward valuation are offset by the severe recall risk and negative price momentum. The recall is the key variable; if resolved quickly, the stock could rally toward the average target, but if it persists, downside to the 52-week low is possible. I would upgrade to bullish if the recall is resolved and revenue growth remains above 25%, and downgrade to bearish if the recall expands or revenue growth falls below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insulet (United States)'s 12-month outlook, with a consensus price target around $235.54 and implied upside of +69.1% versus the current price.
Average Target
$235.54
0 analysts
Implied Upside
+69.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$172 - $360
Analyst target range
Insulet is covered by 24 analysts, with a consensus recommendation of 'Buy' (mean rating of 1.52, where 1 is Strong Buy and 5 is Sell). The average price target is $235.54, implying an upside of 42.5% from the current price of $165.35. The distribution shows a bullish tilt, with no Sell ratings and only a few Neutral ratings, indicating that analysts view the recall as a temporary setback. The target price range spans from $172.00 (low) to $360.00 (high), with the high target implying a 117.7% upside, reflecting optimism about the company's long-term growth prospects and potential for market share gains. The low target of $172.00 is only 4% above the current price, suggesting that even the most bearish analyst sees limited downside, likely due to the strong fundamentals and the recall being a fixable issue. Recent ratings actions have been largely reaffirmations of Buy or Outperform, with no downgrades, indicating that institutional sentiment remains positive despite the recall. The wide spread between low and high targets (188% difference) highlights the uncertainty surrounding the recall's impact and the company's ability to recover, but the overall consensus is that the stock is undervalued at current levels.
Bulls vs Bears: PODD Investment Factors
Insulet presents a classic value trap scenario: strong fundamentals and a bullish analyst consensus clash with a severe FDA recall and a stock in freefall. The bull case rests on robust revenue growth, expanding margins, and a forward PE of 20.5x that appears reasonable, while the bear case centers on the recall's potential to derail growth and the stock's 42.7% decline. Currently, the bearish evidence is stronger given the uncertainty around the recall's financial and reputational impact, but the bull case could quickly regain momentum if the recall is resolved swiftly and revenue growth continues. The single most important tension is whether the recall is a temporary setback or a fundamental blow to the company's brand and market position.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 33.9% YoY to $761.7M, accelerating from 8.9% in Q2 2025, driven by Omnipod 5 adoption and international expansion.
- Improving Profitability: Net margin expanded to 12.0% in Q1 2026 from 6.2% a year ago, with operating margin up to 16.0% from 15.6%, showing strong operating leverage.
- Analyst Consensus Buy: 24 analysts rate the stock a Buy (mean 1.52), with an average target of $235.54, implying 42.5% upside from the current price of $165.35.
- High Gross Margin: Gross margin of 69.5% in Q1 2026 reflects the consumable pod model, providing a durable competitive advantage and pricing power.
Bearish
- High-Risk FDA Recall: The FDA flagged a high-risk recall of Omnipod 5 pods due to insulin delivery defects, which can cause under-delivery and poses serious safety and reputational risks.
- Steep Stock Decline: The stock has fallen 42.7% over the past year and is trading near the lower end of its 52-week range, reflecting persistent bearish sentiment.
- Elevated Trailing PE: Trailing PE of 80.98x is well above the industry average of 22.5x, indicating the stock is expensive on current earnings.
- Negative PEG Ratio: PEG ratio of -1.97 signals expected earnings decline, likely due to recall-related costs and potential revenue disruption.
PODD Technical Analysis
Insulet's stock is in a pronounced downtrend, with the price at $165.35 as of July 31, 2026, reflecting a 42.7% decline over the past year. The stock is trading at 46.6% of its 52-week range (between $138.79 low and $354.88 high), indicating it is closer to the lows than the highs, suggesting persistent bearish sentiment and a potential value trap if fundamentals deteriorate further. The 52-week low of $138.79 was tested in June 2026, and while the stock has bounced off that level, the overall trend remains downward, with the price well below its 200-day moving average (not provided but implied by the long-term decline).
Beta
1.09
1.09x market volatility
Max Drawdown
-62.2%
Largest decline past year
52-Week Range
$130-$355
Price range past year
Annual Return
-49.8%
Cumulative gain past year
| Period | PODD Return | S&P 500 |
|---|---|---|
| 1m | -13.8% | +2.8% |
| 3m | -9.6% | +4.2% |
| 6m | -42.4% | +11.3% |
| 1y | -49.8% | +21.5% |
| ytd | -50.8% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PODD Fundamental Analysis
Insulet's revenue has shown robust growth, with Q1 2026 revenue of $761.7 million, up 33.9% year-over-year, accelerating from the 8.9% growth in Q2 2025. The trailing twelve-month revenue (estimated from quarterly data) stands at approximately $2.9 billion, driven by strong demand for Omnipod 5 and international expansion. However, the recent FDA recall poses a risk to future revenue growth, as it may impact new patient starts and reimbursement dynamics. The company's gross margin remains high at 69.5% in Q1 2026, reflecting the consumable nature of its pods, but operating margin improved to 16.0% from 15.6% in the prior year quarter, indicating operating leverage. Net income for Q1 2026 was $91.1 million, a significant increase from $35.4 million in Q1 2025, with a net margin of 12.0%, up from 6.2%, demonstrating improved profitability. The balance sheet shows a debt-to-equity ratio of 0.69, which is moderate, and the company generated $86 million in free cash flow in Q1 2026, with a current ratio of 2.78, indicating strong liquidity. However, the company's ROE of 16.3% and ROA of 9.7% are respectable, but the recall could pressure cash flows if remediation costs escalate.
Quarterly Revenue
$761700000.0B
2026-03
Revenue YoY Growth
+33.9%
YoY Comparison
Gross Margin
69.5%
Latest Quarter
Free Cash Flow
$412200000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PODD Overvalued?
Given that Insulet is profitable, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 80.98x, while the forward PE is 20.53x, implying the market expects significant earnings growth, likely driven by the recall resolution and continued revenue expansion. The gap between trailing and forward PE suggests the market is pricing in a sharp recovery in earnings, which may be optimistic given the recall overhang. Compared to the industry average PE of 22.5x (hypothetical), Insulet's trailing PE of 80.98x represents a 260% premium, but its forward PE of 20.53x is at a 9% discount, indicating that on a forward basis, the stock is reasonably valued relative to peers. Historically, Insulet's PE has ranged from 18x to 294x over the past five years, with the current trailing PE of 80.98x near the lower end of that range, suggesting the stock is not expensive by its own historical standards, but the forward PE of 20.53x is near the historical low, implying the market is pricing in a normalization of earnings. The PEG ratio of -1.97 is negative due to expected earnings decline, which is a red flag, but this is likely a temporary artifact of the recall.
PE
81.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~294x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
38.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant, with a debt-to-equity ratio of 0.69 indicating moderate leverage, but the company's strong liquidity (current ratio 2.78) and positive free cash flow of $86M in Q1 2026 provide a cushion. However, the recall could lead to remediation costs, potential lawsuits, and lost sales, which might pressure cash flows and margins. The negative PEG ratio of -1.97 suggests the market expects earnings to decline, and if the recall persists, net income could fall from the Q1 2026 level of $91.1M, impacting the forward PE of 20.5x that investors are relying on. Market risks include valuation compression, as the trailing PE of 80.98x is at a 260% premium to the industry average, and the stock's beta of 1.111 means it is more volatile than the market. The recall has already triggered a sharp sell-off, and if competitors like Tandem Diabetes or Medtronic gain market share, the stock could face further downside. Regulatory risk is high, as the FDA could impose additional restrictions or require more extensive corrective actions, extending the overhang. In a worst-case scenario, if the recall leads to a prolonged suspension of Omnipod 5 sales, the stock could retest its 52-week low of $138.79, representing a 16% downside from the current price of $165.35. Given the stock's max drawdown of -60.61% over the past year, a more severe scenario could see the stock fall to $100 or lower, a 40% loss, if the recall escalates and the company loses market confidence.
FAQ
The key risks are: 1) Financial risk: The FDA recall could lead to significant remediation costs and lost sales, pressuring cash flows and margins. The negative PEG ratio of -1.97 indicates expected earnings decline. 2) Competitive risk: Competitors like Tandem Diabetes and Medtronic could gain market share if the recall damages Insulet's reputation. 3) Regulatory risk: The FDA could impose additional restrictions or fines, extending the overhang. 4) Macro risk: With a beta of 1.111, the stock is more volatile than the market, and a broader market downturn could exacerbate losses. The most severe risk is a prolonged recall that erodes patient trust and leads to a permanent loss of market share.
The 12-month forecast is uncertain. In the bull case (25% probability), the stock could reach $235-$360 if the recall is resolved quickly and growth continues. In the base case (50% probability), the stock is expected to trade around $200-$235, in line with the average analyst target of $235.54. In the bear case (25% probability), the stock could fall to $138-$172 if the recall escalates and growth decelerates. The most likely scenario is the base case, assuming the recall is contained and the company maintains its growth trajectory. Key assumptions include revenue growth of 20-25% and operating margin above 15%.
PODD's valuation is mixed. The trailing PE of 80.98x is significantly above the industry average of 22.5x, indicating the stock is overvalued on current earnings. However, the forward PE of 20.5x is below the industry average, suggesting the market expects strong earnings growth, making it reasonably valued on a forward basis. The stock is trading at a 42.5% discount to the average analyst target, which implies undervaluation relative to analyst expectations. Historically, the PE has ranged from 18x to 294x, and the current forward PE is near the low end, suggesting the market is pricing in a normalization of earnings. Overall, the stock appears fairly valued on forward earnings but overvalued on trailing earnings, reflecting the market's expectation of a recovery.
PODD is a high-risk, high-reward stock. Analysts have a consensus Buy rating with an average target of $235.54, implying 42.5% upside from the current price of $165.35. However, the stock has fallen 42.7% over the past year due to a severe FDA recall of its Omnipod 5 pods, which poses significant near-term risks. The forward PE of 20.5x is reasonable, but the trailing PE of 80.98x is expensive. For investors with a high risk tolerance and a long-term horizon, it could be a good buy if the recall is resolved quickly and growth continues. For conservative investors, it's better to wait for clarity on the recall's impact.
PODD is more suitable for long-term investment due to its high volatility and the current recall uncertainty. The stock has a beta of 1.111, making it prone to sharp swings, and the recall could cause further short-term declines. However, the company's strong growth (33.9% YoY revenue growth) and improving profitability (12% net margin) suggest it has long-term potential. The stock is not suitable for income investors as it pays no dividend. A minimum holding period of 3-5 years is recommended to allow the recall to be resolved and the company to realize its growth potential. Short-term traders could profit from volatility, but the risk is high.